Mean±SD or n (%) | |
Total | |
Socio-demographic factors | |
Age (years) | 43.9±12.8 |
Gender, n: 5555 Female | 3080 (55.4) |
Educational level University | 2569 (46.2) |
Employment status, n: 5183 | |
Employed | 2641 (51.0) |
Temporary sick leave | 653 (12.6) |
Permanent sick leave | 415 (8.0) |
Retired or early retired | 616 (11.9) |
Unemployed | 373 (7.2) |
Homemaker | 365 (7.0) |
Student | 120 (2.3) |
Patient organisation membership | |
Yes | 2407 (43.3) |
Lifestyle factors | |
Physical activity, n: 5476 | 4468 (81.6) |
Smoking, n: 5288 | 1128 (21.3) |
Alcohol, n: 5462 | 1631 (29.9) |
Patient-reported outcomes | |
BASDAI (0–10), n: 5295 | 5.4±2.1 |
Spinal Stiffness Index (3–12), n: 5371 | 7.6±2.5 |
Functional Limitation Index (0–54), n: 5482 | 19.8±15.4 |
Disease characteristics | |
Diagnostic delay (years), n: 5327 | 7.4±9.0 |
Symptom duration (years), n: 5421 | 17.1±13.3 |
Extra-musculoskeletal manifestations | |
Uveitis, n=5050 | 1171 (23.2) |
Inflammatory bowel diseases, n=5156 | 724 (14.0) |
Treatments | |
Use of NSAIDs, n: 4995 | 3921 (78.5) |
Use of csDMARDs, n: 4922 | 2137 (43.4) |
Use of bDMARDs, n: 5034 | 2456 (48.8) |
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; NSAIDs, non-steroidal anti-inflammatory drugs.